AstraZeneca Pharmaceuticals' Atlantic trial to determine the safety and effectiveness of durvalumab as a late-stage therapy to treat metastatic programmed death ligand-1 (PD-L1) positive non-small cell lung cancer (NSCLC) has yielded preliminary results.
"As we have seen in other studies, durvalumab has demonstrated expected clinical activity and durable response in these heavily pre-treated patients," Sean Bohen, chief medical officer of AstraZeneca, said. "As previously communicated, the treatment and regulatory landscape in lung cancer is evolving. We now believe it is unlikely that Atlantic can be used for regulatory submission as a monotherapy, but we will make that determination following a full analysis of the data. Durvalumab is a cornerstone of our immuno-oncology portfolio with a fast-advancing development program focused primarily on novel combinations."
A complete assessment of Atlantic data is pending. AstraZeneca researchers will present this information at a scientific congress next year.
AstraZeneca is also testing durvalumab in 16 clinical trials involving 9,000 patients with lung, bladder, head, neck and other cancers.
AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.
